BMO Capital keeps BrightSpring Health at "outperform" and raises price target from $80 to $84
BMO Capital maintained its "outperform" rating on BrightSpring Health and raised its price target from $80 to $84, a 5.0% increase. The new target implies 20.3% upside from the November 17 close of $69.83. The five most recent analyst notes on the company over the past 30 days set price targets between $82 and $92.
In 25 seconds
- BMO Capital reiterates its "outperform" rating on BrightSpring Health.
- The price target rises from $80 to $84, a 5.0% increase.
- The new target implies 20.3% upside from the November 17 close of $69.83.
IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.